We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App





Sekisui Diagnostics Displays Full Range of Clinical Chemistry, Point-of-Care, and Biochemical Solutions

By LabMedica International staff writers
Posted on 19 Nov 2025

At MEDICA 2025, Sekisui Diagnostics is presenting a broad lineup of in-vitro diagnostic products spanning clinical chemistry reagents, point-of-care testing solutions, enzymes and specialty biochemicals, biopharmaceutical services, and blood collection tube raw materials. More...

Exhibiting in Hall 1, Stand D57, the company draws on more than 40 years of global diagnostics expertise to support physicians, hospitals, laboratories, and decentralized testing environments.

At the booth, visitors can explore the OSOM rapid-test family, which provides fast, lateral-flow diagnostics for a wide range of infectious diseases, including influenza, Group A Strep, and Trichomonas vaginalis. For clinical chemistry, Sekisui is also highlighting its SEKURE reagent kits, which offer liquid-stable technology, strong performance, proven reliability, and comprehensive support services. Calibrators, controls, and linearity materials are also on display to complement instrument-based testing.

Sekisui is also prominently featuring point-of-care and home-testing solutions at MEDICA 2025. The OSOM brand extends into home-use products, including antigen- and molecular-based kits for COVID-19 and other respiratory pathogens. Sekisui also introduces its Metrix molecular platform and the Acucy diagnostic reader, both designed to support instrument-enabled point-of-care workflows in decentralized settings.

High-quality enzymes and specialty biochemicals form another key part of the portfolio, with products tailored for a variety of applications, including pharmaceutical manufacturing, clinical chemistry reagents, and POC/biosensor devices. The company is also highlighting its raw materials for plastic vacuum blood-collection tubes and related pre-analytic systems, which are trusted by blood-collection tube manufacturers worldwide. Sekisui’s raw materials offer excellent performance characteristics that support stable, reliable serum generation with very low influence on clinical test results, contributing to more accurate diagnostics and improved patient outcomes.

Related Links:
Sekisui Diagnostics


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.